Ascletis Pharma Inc.
HKEX:1672.HK
1 (HKD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||
| Net Income
| -144.715 | -314.843 | -199.017 | -209.241 | -95.969 | -19.87 | -80.441 | -31.873 |
| Depreciation & Amortization
| 18.48 | 30.191 | 29.545 | 27.163 | 22.148 | 11.98 | 5.55 | 2.471 |
| Deferred Income Tax
| 0 | 0 | 47.537 | 122.465 | 76.669 | -1.809 | -15.613 | 0 |
| Stock Based Compensation
| 1.331 | 3.193 | 7.13 | 4.612 | 3.124 | 4.266 | 1.163 | 0 |
| Change In Working Capital
| 34.452 | 33.807 | -10.175 | 10.426 | -8.418 | -66.157 | -98.439 | 17.088 |
| Accounts Receivables
| 18.444 | 29.744 | -26.993 | 42.984 | -11.902 | -57.623 | 0 | 0 |
| Inventory
| -8.054 | -12.839 | -5.068 | -18.373 | -2.162 | -21.666 | -43.464 | -16.086 |
| Accounts Payables
| 0 | -29.744 | 26.993 | -42.984 | 11.902 | 0 | 0 | 0 |
| Other Working Capital
| 28.136 | 46.646 | -5.107 | 28.799 | -6.256 | -44.491 | -54.975 | 33.174 |
| Other Non Cash Items
| -98.836 | 105.199 | -21.95 | -40.336 | -71.895 | -25 | -10.276 | -0.184 |
| Operating Cash Flow
| -144.162 | -142.453 | -146.93 | -84.911 | -74.341 | -96.59 | -198.056 | -12.498 |
| Investing Activities: | ||||||||
| Investments In Property Plant And Equipment
| -19.158 | -14.401 | -7.198 | -38.96 | -28.233 | -60.083 | -35.949 | -44.606 |
| Acquisitions Net
| 0 | 0 | 2.23 | -19.652 | -67.4 | -44.267 | -9.236 | -4.241 |
| Purchases Of Investments
| -997.222 | -1,762.4 | -601.978 | -75.418 | 9.348 | -1,132.579 | -1,331.278 | -5.61 |
| Sales Maturities Of Investments
| 1,166.101 | 479.322 | 332.2 | 190.613 | 697.237 | 372 | 706.11 | 14 |
| Other Investing Activites
| 156.058 | 0.092 | 0.254 | 75.714 | -8.683 | 47.458 | 25.811 | 2.824 |
| Investing Cash Flow
| 149.845 | -1,297.387 | -274.492 | 132.297 | 602.269 | -817.471 | -644.542 | -37.633 |
| Financing Activities: | ||||||||
| Debt Repayment
| -2.391 | -2.223 | -2.284 | -1.934 | -1.948 | 0 | 0 | 0 |
| Common Stock Issued
| 0 | 0.961 | 0 | 0 | 0 | 2,970.782 | 0 | 0 |
| Common Stock Repurchased
| -78.961 | 0 | -28.689 | -19.601 | -46.269 | 0 | 0 | -242.564 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | -57.815 | 0 | -64.476 |
| Other Financing Activities
| -0.144 | -0.157 | -0.125 | -0.135 | -48.217 | -352.825 | 549.362 | 395.199 |
| Financing Cash Flow
| -81.496 | -1.419 | -31.098 | -21.67 | -48.217 | 2,560.142 | 549.362 | 88.159 |
| Other Information: | ||||||||
| Effect Of Forex Changes On Cash
| 2.162 | 117.616 | -30.573 | -110.256 | 33.441 | 12.114 | -2.04 | 8.547 |
| Net Change In Cash
| -73.651 | -1,323.643 | -483.093 | -84.54 | 513.152 | 1,658.195 | -295.276 | 46.575 |
| Cash At End Of Period
| 330.117 | 403.768 | 1,727.411 | 2,210.504 | 2,295.044 | 1,781.892 | 123.697 | 418.973 |